Fig. 6.
Anti-PD-1 boosts the efficacy of vaccination against site I only when a site IV-specific response is co-present. B6 mice were injected i.v. with site I peptide-pulsed BMDCs (A) or infected i.p. with either rVV-I minigene (B) or rVV-FL T Ag (C) before they received treatment with anti-PD-1 or isotype control (n=4–8 per cohort as indicated). Seven days later, T Ag-specific TCD8 responses were quantified by ICS after ex vivo stimulation of splenocytes with indicated T Ag-derived peptides or T Ag+ cell lines. * denotes p<0.05 by Student’s t-test (C). NS: non-significant (A–B). Error bars (A–C) represent SEM.